Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.74 |
| ▸ | CDK2 | P24941 | 6/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13122097 | 1.00 | GSK3B (0.74) | GSK3BCDK2CCNE1 | |
| SCHEMBL14562307 | 0.91 | GSK3B (0.69) | GSK3BCDK2CCNE1 | |
| SCHEMBL13289460 | 0.90 | GSK3B (0.59) | GSK3BCDK2CCNE1 | |
| SCHEMBL13122092 | 0.88 | GSK3B (0.75) | GSK3BCDK2CCNE1 | |
| SCHEMBL13122098 | 0.86 | GSK3B (0.84) | GSK3BCDK2CCNE1 | |
| SCHEMBL13122091 | 0.86 | GSK3B (0.82) | GSK3BCDK2CCNE1 | |
| SCHEMBL12953687 | 0.86 | GSK3B (0.73) | GSK3BCDK2CCNE1 | |
| SCHEMBL13122110 | 0.86 | GSK3B (0.75) | GSK3BCDK2CCNE1 | |
| SCHEMBL12953729 | 0.86 | GSK3B (1.00) | GSK3BCDK2CCNE1 | |
| SCHEMBL13122104 | 0.85 | GSK3B (0.77) | GSK3BCDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820817-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100105693-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| EP-1753429-A1 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
| WO-2005117883-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105693-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | GSK3B 4166/4885CDK2 2455/4885CCNE1 4552/4885 |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | ACHE, CHRM5, CHRM3 | GSK3B 3225/4885CDK2 1519/4885CCNE1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.